VT-1598 is under clinical development by Mycovia Pharmaceuticals and currently in Phase I for Candidiasis. According to GlobalData, Phase I drugs for Candidiasis have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VT-1598’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VT-1598 overview

VT-1598 is under development for the treatment of invasive fungal infections such as coccidioidomycosis or valley fever and cryptococcal meningitis and infections against species such as Cryptococcus, Aspergillus, Rhizopus, and Candida. The drug candidate is administered through oral in the form of tablet and intravenous route. It is second-generation small molecule and targets lanosterol demethylase (CYP51). It is based on Metallophile technology platform.

Mycovia Pharmaceuticals overview

Mycovia Pharmaceuticals(Mycoyia Pharmaceuticals) formerly known as Viamet Pharmaceuticals, is a subsidiary of Viamet Pharmaceuticals Holdings LLC, discovers and develops novel medicinal drugs based on metalloenzyme chemistry and biology technology platform. Its product portfolio includes clinical-stage compounds such as VT-1161, an oral inhibitor used for the treatment of onychomycosis and recurrent vulvovaginal candidiasis; VT-1129, an oral agent for the treatment of cryptococcal meningitis; VT-1598, an oral inhibitor to treat invasive fungal infections, including coccidioidomycosis. The company’s proprietary MIDAS technology (Metalloenzyme Inhibitor Design and Synthesis) enables to discover metalloenzyme inhibitors that target fungal CYP51 of both chronic and life threatening fungal infections. Mycoyia Pharmaceuticals is headquartered in Durham, North Carolina, the US.

For a complete picture of VT-1598’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.